Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis

Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention

“…The baseline lipid profile difference could account for the different lipid lowering strategies prescribed by physicians in three groups of patients. Ji et al found in their study that the LDL-C reduction was similar between ezetimibe-statin combination group and intensive statin group for patients suffered acute myocardial infarction (9), which was consistent with this study. In our study, the proportion of patients reaching LDL-C goal was higher in ezetimibe-statin combination group than moderate-intensity statin group, and this result was similar to other published studies (21).…”

“…Numerous studies have shown that statins can significantly reduce LDL-C levels and slow down process of coronary plaque formation, thus ameliorating the risk of cardiovascular events (6)(7)(8)(9). According to 2013 American College of Cardiology (ACC) guideline, intensive statin therapy has been recommended to patients with ASCVD for lowering blood cholesterol (5).…”

Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure

“…It is induced by severe and everlasting acute ischemia caused by the sudden reduction or occlusion of coronary arterial blood supply based on coronary artery atherosclerosis. AMI is the primary cause of the death of patients with cardiovascular disease 1,2. AMI can be classified into acute ST-segment elevation myocardial infarction (STEMI) and non-ST segment elevation myocardial infarction (NSTEMI).…”

Statin Use and the Risk of Prostate Cancer in Ischemic Heart Disease Patients in Taiwan

“…Statins would also be categorized into three intensity groups—high, moderate, and low, based on guidelines and observational studies . High‐intensity statins include atorvastatin 40 mg, rosuvastatin 20 mg, simvastatin 80 mg, and simvastatin 20 mg plus ezetimibe; moderate‐intensity statins include atorvastatin 10–20 mg, rosuvastatin 5–10 mg, fluvastatin 80 mg, lovastatin 40 mg, pitavastatin 2–4 mg, pravastatin 40 mg, simvastatin 20–40 mg, simvastatin 10 mg plus ezetimibe, atorvastatin 10 mg plus amlodipine, atorvastatin 20 mg plus amlodipine, and pravastatin 40 mg plus fenofibrate; low‐intensity statins include pravastatin 10–20 mg, simvastatin 10 mg, lovastatin 20 mg, fluvastatin 20–40 mg, and lovastatin 20 mg plus niacin.…”